Speeding Diagnosis & Predicting Survival Outcomes With AI : Oncology Times
An abstract is unavailable.
Related Articles
Personalized Immunotherapy Earns FDA RMAT Status in Advanced Ovarian Cancer
Phase 2b data support the Regenerative Medicine Advanced Therapy designation for gemogenovatucel-T in newly diagnosed advanced ovarian cancer.
Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors
This article reports a multi-institutional retrospective comparison of the activity between sorafenib and anthracycline-based chemotherapies for desmoid tumors. It shows that anthracycline-based chem…
Neoadjuvant Chemoradiotherapy With or Without Sintilimab for Esophageal Squamous Cell Carcinoma
Xuefeng Leng, MD, explains results from the phase 3 SCIENCE trial, evaluating neoadjuvant chemoradiotherapy and chemotherapy with sintilimab for esophageal squamous cell carcinoma.
American Cancer Society guideline for diet and physical activity for cancer prevention
The American Cancer Society (ACS) publishes the Diet and Physical Activity Guideline to serve as a foundation for its communication, policy, and community strategies and,…
Over a quarter of stem cell transplant survivors develop cutaneous malignant neoplasms
More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms, according to study results.Researchers identified several risk factors, including older age, development…
ASCO GI 2025: Practice-Changing Advances in Colorectal Cancer
Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.
Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases
Sanchez-Laorden and colleagues reveal that microglial Rela/NF-κB activation promotes melanoma brain metastasis . Targeting this pathway reprograms microglia, enhancing antitumor immunity, reducing metastases, and improving…
Engineered Focal Oncogene Amplifications Drive Transformation and Progression
Main Findings: Engineering oncogene-containing extrachromosomal DNA generates preclinical immunocompetent mouse models of cancer.Concept: Cre-mediated recombination of a region flanked by loxP sites of the same…
Clinical Outcomes of Stage IIA/IIB Seminoma Treated With Radiation Therapy and Chemotherapy: Should Regional Therapy be Considered the Preferred Treatment Approach?
The optimal management of patients with de novo clinical stage IIA/B (CSIIA/B) or relapsed CSIIA/B (Rel-CSIIA/B) seminoma remains debated because of a lack of randomized…
Poor Outcomes Seen in BRAF V600E-Mutant mCRC With Systemic Therapy
Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, according to real-world data.
